502 related articles for article (PubMed ID: 19417020)
21. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
22. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
23. Dehydrobruceine B enhances the cisplatin-induced cytotoxicity through regulation of the mitochondrial apoptotic pathway in lung cancer A549 cells.
Huang Z; Yang G; Shen T; Wang X; Li H; Ren D
Biomed Pharmacother; 2017 May; 89():623-631. PubMed ID: 28262615
[TBL] [Abstract][Full Text] [Related]
24. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
27. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells.
Akhdar H; Loyer P; Rauch C; Corlu A; Guillouzo A; Morel F
Eur J Cancer; 2009 Aug; 45(12):2219-27. PubMed ID: 19524433
[TBL] [Abstract][Full Text] [Related]
28. [Small interfering RNA-mediated Nrf2 gene knockdown enhances hirsutanols A-induced cytotoxicity in cancer cells].
Ma J; Li H; Deng R; Feng G; Zhu X
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Aug; 32(8):1093-7. PubMed ID: 22931598
[TBL] [Abstract][Full Text] [Related]
29. 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells.
Lim J; Lee SH; Cho S; Lee IS; Kang BY; Choi HJ
Mol Cells; 2013 Oct; 36(4):340-6. PubMed ID: 24046186
[TBL] [Abstract][Full Text] [Related]
30. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
31. Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells.
Gao Y; Li W; Liu X; Gao F; Zhao X
Mol Med Rep; 2015 Mar; 11(3):2118-24. PubMed ID: 25394367
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of second mitochondria-derived activator of caspase expression by RNAi enhances growth and cisplatin resistance of human lung cancer cells.
Zeng H; Zhang S; Yang KY; Wang T; Hu JL; Huang LL; Wu G
Cancer Biother Radiopharm; 2010 Dec; 25(6):705-12. PubMed ID: 21204765
[TBL] [Abstract][Full Text] [Related]
33. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells.
He L; Meng Y; Zhang Z; Liu Y; Wang X
J Cancer Res Ther; 2018; 14(7):1519-1524. PubMed ID: 30589033
[TBL] [Abstract][Full Text] [Related]
35. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
36. Suppression of OCT4B enhances sensitivity of lung adenocarcinoma A549 cells to cisplatin via increased apoptosis.
Cortes-Dericks L; Yazd EF; Mowla SJ; Schmid RA; Karoubi G
Anticancer Res; 2013 Dec; 33(12):5365-73. PubMed ID: 24324071
[TBL] [Abstract][Full Text] [Related]
37. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
38. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation.
Li W; Hardwick MJ; Rosenthal D; Culty M; Papadopoulos V
Biochem Pharmacol; 2007 Feb; 73(4):491-503. PubMed ID: 17126818
[TBL] [Abstract][Full Text] [Related]
39. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate.
Kweon MH; Adhami VM; Lee JS; Mukhtar H
J Biol Chem; 2006 Nov; 281(44):33761-72. PubMed ID: 16950787
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
